Adma Biologics (ADMA) Inventory (2011 - 2025)

Adma Biologics' Inventory history runs 14 years deep, the most recent figure standing at $206.5 million for Q4 2025.

• Quarterly Inventory rose 21.28% year-over-year to $206.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $206.5 million (up 21.28% YoY) and the FY2025 annual result came in at $206.5 million, up 21.28% from the prior year.
• Inventory was $206.5 million for Q4 2025 at Adma Biologics, up from $196.7 million in the prior quarter.
• Across five years, Inventory topped out at $206.5 million in Q4 2025 and bottomed at $94.1 million in Q1 2021.
• A 5-year average of $158.6 million and a median of $163.6 million in 2022 frame the typical range for Inventory.
• Annual changes were most pronounced in 2021 — Inventory soared 80.05% — and 2025, when it retreated 3.12%.
• Adma Biologics' Inventory stood at $124.7 million in 2021, then surged by 30.91% to $163.3 million in 2022, then advanced by 5.9% to $172.9 million in 2023, then declined by 1.54% to $170.2 million in 2024, then advanced by 21.28% to $206.5 million in 2025.
• Business Quant data shows ADMA's Inventory at $206.5 million in Q4 2025, $196.7 million in Q3 2025, and $191.5 million in Q2 2025.